Deprenyl Research Ltd. announced Friday that it willdiscontinue at the end of the year its co-marketingarrangement with its Canadian marketing partner, PurdueFredrick, for Deprenyl's Parkinson's disease treatment,Eldepryl.

Deprenyl Research of Toronto received Canadian marketingapproval in April for Eldepryl as a first-line treatment forParkinson's disease, a drug that the company anticipated wouldbe used by 30,000 Canadian patients and which garnered salesof $11.6 million in 1991.

(c) 1997 American Health Consultants. All rights reserved.

No Comments